返回 Agenda
Session 9: Development of the Risk Management Strategy
Session Chair(s)
Carla Barrett, PHARMD
Vice President, Global Risk Management
Novavax, United States
- This session will provide details on how to develop the risk management strategy by defining a product’s risks to patients, developing a plan for pharmacovigilance, developing a plan for risk minimization, determining how to implement the actions, and addressing regional variations of risk management strategies.